Bone metastatic prostate cancer: New research directions for a tough problem
American Cancer Society scientists project that approximately 33,330 men will die from prostate cancer in America in 2020. The majority of these deaths are due to the development of advanced stage castration-resistant disease, which typically progresses to bone metastatic prostate cancer. \n\nIn this conversation, two-time American Cancer Society grantee Leah Cook, PhD, talks us through the problem of bone metastatic prostate cancer. Why is it so hard to treat? What is happening inside the bones? And why is she excited about recent discoveries made in her lab?\n\nLeah Cook, PhD, is Assistant Professor in the Department of Pathology and Microbiology at the Univ. of Nebraska Medical Center.\n\n3:36 - Where in the body does prostate cancer most frequently go when it moves?\n\n4:49 \u2013 How many men with prostate cancer will experience bone metastatic disease? \n\n5:52 \u2013 On how bone metastatic prostate cancer is treated\n\n8:30 \u2013 On what happens to bones when prostate cancer cells invade\n\n10:32 \u2013 On why immune cells are present in bone cells\n\n12:11 \u2013 On how her lab is trying to understand what happens to immune cells in bones that have been invaded by prostate cancer\n\n13:52 \u2013 Why don\u2019t immune cells in the bone recognize and kill bone metastatic prostate cancer cells?\n\n19:23 \u2013 How could the work of her lab change how we treat metastatic prostate cancer?\n\n21:48 \u2013 What she\u2019s most excited about in her research\n\n23:42 \u2013 The role of ACS funding in her career\n\n25:11 \u2013 A message she\u2019d like to share with cancer survivors and caregivers\n\n27:32 \u2013 On health equity issues in metastatic prostate cancer, especially among African American men